Anticoagulation for atrial fibrillation with intermediate stroke risk: The SINGLE-AF trial
The SINGLE-AF trial demonstrated that anticoagulation with a DOAC significantly reduced the 24-month risk of stroke, systemic embolism, major bleeding, or cardiovascular death compared with no anticoagulation in patients with atrial fibrillation (AF) at intermediate risk of stroke, according to a study presented by Dr. Boyoung Joung, Yonsei University College of Medicine, South Korea, in the Hot Line session at ESC Congress 2026.
- Free Registration
-
Already have an account?Log In
A portal site of complex catheter intervention techniques
TCROSS NEWS Global is an online medical journal that provides
valuable information on Cardiovascular medicine to medical professionals
worldwide.
We bring you the latest findings and trends in all areas of
cardiovascular medicine. Please register and subscribe for unlimited access to
quality Cardiovascular News!
We provide timely and up-to-date information to our partners across the world by covering and reporting live sessions and conferences, featuring of complex cases, newsletters, academic researches and case studies.
Recommendations